Four guidelines on cardiovascular complications and cardiovascular disease, prognosis and treatment in COVID‑19

por Siebelink, H. J., Jansen, C. W., Belfroid, E., Hoogervorst-Schilp, J.
Publicado 2021

Impact of cardiovascular disease and cardiovascular risk factors in hospitalised COVID-19 patients

por Jewbali, L. S. D., Hoogervorst-Schilp, J., Belfroid, E., Jansen, C. W., Asselbergs, F. W., Siebelink, H. J.
Publicado 2021

Effect of anticoagulant therapy in COVID-19 patients

por Tieleman, R. G., Klok, F. A., Belfroid, E., Hoogervorst-Schilp, J., Schalkers, I., Jansen, C. W., Siebelink, H. J.
Publicado 2021

How often and to what extent do admitted COVID-19 patients have signs of cardiac injury?

por Habets, M. A. W., Sturkenboom, H. N., Tio, R. A., Belfroid, E., Hoogervorst-Schilp, J., Siebelink, H. J., Jansen, C. W., Smits, P. C.
Publicado 2021